Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b

被引：0
|
作者：
Horsley, Elizabeth
Jabeen, Asma
Veillard, Nicolas
Havenith, Karin
Janghra, Narinder
Alves, Pedro
Oblette, Cecile
Kirby, Ian
Hogg, Paul W.
Zammarchi, Francesca
de Haan, Lolke
van Berkel, Patrick
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Results from the phase 1 dose escalation study of XMT-1592, a dolasynthen NAPI2B-directed antibody-drug conjugate (ADC)
    Hamilton, Erika P.
    Papadopoulos, Kyriakos P.
    Barve, Minal
    Lakhani, Nehal
    Burns, Timothy F.
    Burger, Robert A.
    Reske, Adi
    Wekheye, Kelley
    Tolcher, Anthony
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A343 - A343
  • [22] Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
    Scribner, Juniper A.
    Brown, Jennifer G.
    Sharma, Sharad
    Li, Hua
    Chiechi, Michael
    Li, Pam
    Son, Thomas
    De Costa, Anushka
    Chen, Yan
    Chen, Francine
    Barat, Bhaswati
    Huang, Ling
    Wolff, Christina
    Hooley, Jeff
    Hotaling, Tim E.
    Gaynutdinov, Timur
    Ciccarone, Valentina
    Tamura, James
    Koenig, Scott
    Johnson, Syd
    Moore, Paul A.
    Bonvini, Ezio
    Loo, Deryk
    CANCER RESEARCH, 2018, 78 (13)
  • [23] Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
    Scribner, Juniper A.
    Brown, Jennifer G.
    Son, Thomas
    Chiechi, Michael
    Li, Pam
    Sharma, Sharad
    Li, Hua
    De Costa, Anushka
    Li, Ying
    Chen, Yan
    Easton, Ann
    Yee-Toy, Nicholas C.
    Chen, Francine Z.
    Gorlatov, Sergey
    Barat, Bhaswati
    Huang, Ling
    Wolff, Christina R.
    Hooley, Jeff
    Hotaling, Tim E.
    Gaynutdinov, Timur
    Ciccarone, Valentina
    Tamura, James
    Koenig, Scott
    Moore, Paul A.
    Bonvini, Ezio
    Loo, Deryk
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2235 - 2244
  • [24] XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma
    Fessler, Shawn
    Dirksen, Anouk
    Collins, Scott D.
    Xu, Ling
    Lee, Winnie
    Wang, Jason
    Eydelloth, Ron
    Ter-Ovanesyen, Elena
    Zurita, Jeffrey
    Ditty, Elizabeth
    Nehilla, Barrett
    Clardy, Susan
    Carter, Tyler
    Avocetien, Kenneth
    Nazzaro, Mark
    Le, Nam
    Catcott, Kalli C.
    Uttard, Alex
    Du, Bingfan
    Chin, Chen-Ni
    Mosher, Rebecca
    Slocum, Kelly
    Qin, Liuliang
    Lee, David
    Toader, Dorin
    Damelin, Marc
    Lowinger, Timothy B.
    CANCER RESEARCH, 2020, 80 (16)
  • [25] Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo
    Attinger-Toller, Isabella
    Probst, Philipp
    Kallenberger, Lia
    Renard, Emma
    Bertrand, Romain
    Fay, Rachael
    Santimaria, Roger
    Maurhofer, Patrick
    Grabulovski, Dragan
    Schlereth, Bernd
    Spycher, Philipp Rene
    CANCER RESEARCH, 2024, 84 (07)
  • [26] Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers
    Zammarchi, Francesca
    Havenith, Karin E. G.
    Chivers, Simon
    Hogg, Paul
    Bertelli, Francois
    Tyrer, Peter
    Janghra, Narinder
    Reinert, Halla W.
    Hartley, John A.
    van Berkel, Patrick H.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (04) : 582 - 593
  • [27] Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors
    Xu, Jian
    Zong, Qing
    Wang, Wei
    Liu, Qigang
    Stann, Sasha
    Cai, Jiaqiang
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
    Zammarchi, Francesca
    Havenith, Karin
    Chivers, Simon
    Hogg, Paul W.
    Britten, Charlie
    Dissanayake, Sandamali
    Tyrer, Peter
    Bertelli, Francois
    Hutchinson, Ian
    Masterson, Luke
    Howard, Phil
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2018, 78 (13)
  • [29] ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting low HER2-expressing solid cancers
    Zammarchi, F.
    Chivers, S.
    Williams, D. G.
    Adams, L.
    Mellinas-Gomez, M.
    Tyrer, P.
    Corbett, S.
    D'Hooge, F.
    Dissanayake, S.
    Sims, S.
    Havenith, K.
    Howard, P. W.
    Hartley, J. A.
    Van Berkel, P. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S28 - S28
  • [30] A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial
    Ma, Yuxiang
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Xue, Jinhui
    Meng, Xiangjiao
    Fan, Yun
    Fu, Siqing
    Wu, Lin
    Zheng, Yulong
    Liu, Jian
    Liu, Zhihua
    Zhuang, Wu
    Rosen, Seth
    Qu, Song
    Li, Bihui
    Li, Mingjun
    Zhao, Yanqiu
    Yang, Shujun
    Ji, Yinghua
    Sommerhalder, David
    Luo, Suxia
    Yang, Kunyu
    Li, Jingao
    Lv, Dongqing
    Zhang, Peng
    Zhao, Yuanyuan
    Hong, Shaodong
    Zhang, Yang
    Zhao, Shen
    Chin, Steve
    Zhang, Xian
    Lian, Wei
    Cai, Jiaqiang
    Xue, Tongtong
    Zhang, Li
    Zhao, Hongyun
    NATURE MEDICINE, 2025,
12345